Tech Company Financing Transactions
PRISM BioLab Funding Round
On 1/26/2024, PRISM BioLab landed $10.3 million in Series C financing from Eli Lilly and Company.
Transaction Overview
Company Name
Announced On
1/26/2024
Transaction Type
Venture Equity
Amount
$10,300,000
Round
Series C
Investors
Proceeds Purpose
The company intends to use the funds to expand biology and screening capabilities and advance internal pipeline of PPI inhibitors.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
2-26-1, Muraoka-Higashi
Fujisawa, Kanagawa, 251-8555
Japan
Fujisawa, Kanagawa, 251-8555
Japan
Phone
Undisclosed
Website
Email Address
Not Recorded
Overview
PRISM BioLab was founded in 2006 by a group of scientists dedicated to creating new drugs based on their technology of peptide mimetic small molecules. More than ten years of research and development has resulted in the clinical pipelines and numerous discoveries of potential seed compounds. Through its PepMetics® Platform, PRISM has established a proven technology which has already generated successful compounds for what were previously thought to be "undruggable targets".
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Dai Takehara
Chief Financial Officer
Michihiro Maeda
Chief Technical Officer
Tatsuya Toma
VP - R & D
Hyi-Man Park
Browse more venture capital transactions:
Prev: 1/26/2024: Proof Technology venture capital transaction
Next: 1/26/2024: Digs venture capital transaction
Share this article
Where The Data Comes From
We do our best to record every notable VC transaction. VC investment data records reported here are sourced from company press releases and news coverage. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs